Role of protein tyrosine phosphatase SHP-1 in interleukin-6 regulation of prostate cancer

DSpace Repository

Role of protein tyrosine phosphatase SHP-1 in interleukin-6 regulation of prostate cancer

Show full item record

Files for download

Find Full text There are no files associated with this item.

Facebook

Simple item record

Publication Article, peer reviewed scientific
Title Role of protein tyrosine phosphatase SHP-1 in interleukin-6 regulation of prostate cancer
Author(s) Tassidis, Helena ; Culig, Zoran ; Gjörloff Wingren, Anette ; Härkönen, Pirkko
Date 2010
English abstract
Background Interleukin-6 (IL-6) is a multifunctional cytokine that has been implicated in the modulation of growth and progression of prostate cancer. Decreased expression of the tyrosine phosphatase SHP-1, involved in regulation of cytokine and tyrosine kinase receptor signaling, has been shown to be associated with less favourable outcome for prostate cancer patients. Methods Parental LNCaP and LNCaP-IL6+ subline, derived from parental LNCaP cells by continuous culture of the cells in the presence of recombinant IL-6 were used in the study. Expression of SHP-I, PTEN, STAT3, pSTAT3, ERK, pERK, AKT, pAKT, PTEN and SHP-1 was analysed by immunohistochemistry, Western blot, cDNA microarray quantitative PCR and reverse transcriptase PCR. Proliferation and apoptosis of transfected cells was analysed with caspase3/7 and flow cytometry. Results Phosphorylation of ERK and STAT3 was increased in the LNCaP-IL6+ subline compared to LNCaP cells, whereas pAkt was decresaed. This could be due tore-expression of PTEN in LNCaP-IL6+ cells. Overexpression and inhibition experiments with SHP-1 siRNA showed that SHP-1 reduced proliferation and increased apoptosis in both cell lines. A cDNA analysis revealed 80 up-regulated and 87 down-regulated SHP-1 related genes in the LNCaP-IL6+ cell line compared to LNCaP cells. Conclusions SHP-1 suppresses growth and increases apoptosis in both LNCaP and LNCaP-IL6+ cells which suggests that SHP-1 could provide a therapeutic target for the prostate cancer cells even in the case that have gained an IL-6 related growth advantage.
DOI http://dx.doi.org/10.1002/pros.21184 (link to publisher's fulltext)
Publisher Wiley
Host/Issue The Prostate;14
Volume 70
ISSN 1097-0045
Pages 1491-1500
Language eng (iso)
Subject(s) Medicine
Research Subject Categories::MEDICINE
Handle http://hdl.handle.net/2043/10888 (link to this page)

This item appears in the following Collection(s)

Show full item record

Search


Browse

My Account

Statistics